United States Department of Health and Human Services

Velico Medical launches Blood Center Education Program with South Texas Blood & Tissue

Retrieved on: 
Freitag, Oktober 20, 2023
Plasma, Joint Medical Service (Germany), Biomedical Advanced Research and Development Authority, Temperature, History, Human services, United States Department of Health and Human Services, Administration, Administration for Strategic Preparedness and Response, Spray drying, BioBridge Global, STB, Pharmaceutical industry, Centro Velico Caprera

BOSTON, Oct. 20, 2023 /PRNewswire/ -- Velico Medical is proud to announce the launch of its Blood Center Education Program (BCEP) at South Texas Blood & Tissue (STB&T), a subsidiary of San Antonio non-profit BioBridge Global.

Key Points: 
  • BOSTON, Oct. 20, 2023 /PRNewswire/ -- Velico Medical is proud to announce the launch of its Blood Center Education Program (BCEP) at South Texas Blood & Tissue (STB&T), a subsidiary of San Antonio non-profit BioBridge Global.
  • "This collaboration is the first of its kind in the nation and reflects the shared vision of Velico and STB&T of advancing life-saving blood products through the development process," says Richard Meehan, President and CEO of Velico.
  • Velico's BCEP is designed to generate deep customer feedback on the commissioning and operational aspects of the FrontlineODP™ system for spray drying plasma.
  • "South Texas Blood & Tissue is pleased to collaborate with Velico as a BCEP partner.

Alquist 3D Appoints Patrick Callahan as New Chief Executive Officer

Retrieved on: 
Dienstag, Oktober 17, 2023
Partnership, Army, COVID-19, MBA, White, MS, Printing, Babson College, Human services, Elaine Alquist, Humanity, Strategic planning, CSI, Mannheimer, Health, Simmons University, QNA, BA, City, White House, Centers for Disease Control and Prevention, Workforce, Growth, Task force, Aims Community College, ADG, Cornell University, Federal Emergency Management Agency, United States Department of Health and Human Services, AirBoss of America, Army Reserve Officers' Training Corps, Sale, ROTC, City Of, Research, United States Department of the Army, Housing, The Global War on Terrorism Memorial Foundation, Management

GREELEY, Colo., Oct. 17, 2023 /PRNewswire-PRWeb/ -- In a planned restructuring, Alquist 3D Founder and current CEO, Zachary Mannheimer, is appointing Patrick Callahan as its new chief executive officer. In addition, Mannheimer is transitioning to chairman of the board. The management restructuring is concurrent with Alquist's relocation from Iowa City, Iowa, to Greeley, Colorado, occasioned by a $4+ million incentive package from the State of Colorado and City of Greeley.

Key Points: 
  • GREELEY, Colo., Oct. 17, 2023 /PRNewswire-PRWeb/ -- In a planned restructuring, Alquist 3D Founder and current CEO, Zachary Mannheimer, is appointing Patrick Callahan as its new chief executive officer.
  • "Patrick is the executive leader we need as we scale up our operations to meet the housing demand.
  • -Zachary Mannheimer, Founder & Board Chairman
    "Patrick is the executive leader we need as we scale up our operations to meet the housing demand," said Mannheimer.
  • For two years prior, Callahan helped lead the company as CSI's chief strategic officer, responsible for CSI's international growth, business development, and research and development operations.

ARPA-H Awards $3.5 Million Contract to BelleTorus Corp. (Belle.ai) to Expand Pediatric Healthcare Access Using Artificial Intelligence

Retrieved on: 
Mittwoch, Oktober 11, 2023
Diagnosis, Health, Engineering, Ear, Schonfeld Strategic Advisors, Prevalence, Common, United States Department of Health and Human Services, Human services, Population health, Smartphone, Transport, Weill Cornell Medicine, National Association, Federally Qualified Health Center, Artificial intelligence, Performance-based contracting, DARPA, Community, Advanced Research Projects Agency for Health, Federal, UHP, Health equity, Skin, ARPA, Otitis, Patient, Nursing, Dermatology, ARPA-H

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BelleTorus Corporation (Belle.ai) today announced that the Advanced Research Projects Agency for Health (ARPA-H) has awarded Belle.ai and its partner Urban Health Plan (UHP) a $3.5 million contract to improve pediatric healthcare access using artificial intelligence (AI).

Key Points: 
  • CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BelleTorus Corporation (Belle.ai) today announced that the Advanced Research Projects Agency for Health (ARPA-H) has awarded Belle.ai and its partner Urban Health Plan (UHP) a $3.5 million contract to improve pediatric healthcare access using artificial intelligence (AI).
  • Under the project, Belle.ai and UHP will develop an AI solution designed to enable healthcare providers to remotely examine children with skin, ear, and throat conditions.
  • They account for about 30 million visits to the pediatrician each year.
  • “Prompted by the recent pandemic, telehealth has emerged as a critical tool in healthcare delivery, providing remote access to healthcare services for children and their families.

Hippocratic AI Launches Physician Advisory Council; Nationally Recognized Providers to Help Shape First Safety-Focused LLM for Healthcare

Retrieved on: 
Dienstag, Oktober 10, 2023
Senior, American Academy of Pediatrics, Hospital, The Council, United States Department of Health and Human Services, NYT, Pain, Safety, AAP, Health, Council, Medical director, Artificial intelligence, Patient, Entrepreneurship, Chief medical informatics officer, SVP, Mount Sinai Health System, Learning, LLM, Privacy, Secure access service edge, WebMD, Physician, Cleveland Clinic, PALO, Nursing, Medical device, Medscape, Hippocrates, Spine

PALO ALTO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Hippocratic AI today announced the formation of its Physician Advisory Council to help shape its safety-focused Large Language Model (LLM) for healthcare.

Key Points: 
  • PALO ALTO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Hippocratic AI today announced the formation of its Physician Advisory Council to help shape its safety-focused Large Language Model (LLM) for healthcare.
  • Now, in helping shape the first safety-focused LLM for healthcare, they’re poised to empower the broader healthcare workforce, while simultaneously increasing patient access to high-quality care,” said Meenesh Bhimani MD, Co-Founder and Chief Medical Officer of Hippocratic AI.
  • The Physician Advisory Council further reflects Hippocratic AI’s commitment to building the safest and most medically accurate LLM possible.
  • “I’m thrilled to serve as an advisor to Hippocratic AI and play a role in guiding their LLM innovation.

3EO Health Receives NIH RADx® Tech Award to Expand Application of its 3TR Point of Care Technology

Retrieved on: 
Montag, Oktober 16, 2023
Health, Medical Devices, Health Technology, Other Health, COVID-19, General Health, Biotechnology, Tech, National Institute of Biomedical Imaging and Bioengineering, Physician, Family, Biological engineering, Human services, United States Department of Health and Human Services, Medical imaging, Acceleration, Aetna Health Inc. v. Davila, Controversies regarding COVID-19 contracts in the United Kingdom, Chief Technology Officer of the United States, Federal, Bangladesh Technical Education Board, Overalls, National Institutes of Health, Work, Patient, NIH, Vaccine, Medical device

With the NIH RADx Tech award, 3EO Health will accelerate and expand the development and application of its novel 3TR technology into a multiplex format.

Key Points: 
  • With the NIH RADx Tech award, 3EO Health will accelerate and expand the development and application of its novel 3TR technology into a multiplex format.
  • "We are honored to be chosen as recipients of the RADx Tech award from NIBIB," said Jeremy Schubert, CEO of 3EO Health.
  • "3EO Health's innovative approach holds immense promise for the future of diagnostic testing," said Peter Honkanen M.S.M., B.S.E.E., Chief Technology officer of 3EO Health.
  • 3EO Health Inc. is a “Point of Life” diagnostic company leveraging novel technology to exponentially lower cost and expand clinical and community access to high impact diagnostic tools.

Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract

Retrieved on: 
Dienstag, Oktober 10, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Partnership, ASPR, Infection, Food, Development, Office of Inspector General, U.S. Department of Health and Human Services, Human services, Administration for Strategic Preparedness and Response, Tuberculosis verrucosa cutis, Biomedical Advanced Research and Development Authority, Administration, NDA, Medication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pyelonephritis, BARDA, HHS, United States Department of Health and Human Services, Patient, Urinary tract infection, Pharmaceutical industry

Venatorx has recently completed multiple Phase 1 clinical studies with ceftibuten-ledaborbactam etzadroxil and will advance directly to global Phase 3 clinical trial testing under this contract.

Key Points: 
  • Venatorx has recently completed multiple Phase 1 clinical studies with ceftibuten-ledaborbactam etzadroxil and will advance directly to global Phase 3 clinical trial testing under this contract.
  • “We thank BARDA, ASPR, and HHS for their dedication to scientific innovation and commitment to this private-public partnership.
  • BARDA and Venatorx will share the costs of all studies needed to bring the drug to market, including a planned pivotal global Phase 3 clinical trial to treat cUTI.
  • Venatorx will lead all regulatory activities necessary to seek FDA approval of ceftibuten-ledaborbactam etzadroxil under the contract.

Chapter Revises Its Best-seller on Medicare, Incorporating Fresh Data for 2024

Retrieved on: 
Dienstag, Oktober 10, 2023
General Health, Health, Seniors, Consumer, Human services, Amazon, Multimedia, Medicare, Complicated, Blog, Chapter, United States Department of Health and Human Services, Health insurance

View the full release here: https://www.businesswire.com/news/home/20231005256176/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231005256176/en/
    "It's Not That Complicated" 2024 book cover.
  • As we approach a fresh enrollment cycle, Parker anticipates a surge in need for Medicare information , particularly regarding changes to prescription coverage.
  • Chapter also releases a weekly newsletter and blog about the ins and outs of Medicare.
  • “We’re committed to helping people make wise decisions for the next chapter of their lives.”

Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

Retrieved on: 
Mittwoch, Oktober 4, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Clinical Trials, Other Health, Enterprise Ireland, Human services, United States Department of Health and Human Services, History, CDC, Patient, Cancer, Systematic review, Growth, FDA, Pharmaceutical industry, NIOSH

The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to market that will address drug shortages, and improving the preparation and application of oncology medication(1).

Key Points: 
  • The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to market that will address drug shortages, and improving the preparation and application of oncology medication(1).
  • “We are thrilled to announce the successful conclusion of our Series B funding round," stated Sharon Cunningham, chief executive officer of Shorla Oncology.
  • Shorla recently announced the FDA approval and market launch of Nelarabine Injection, marking its first approval in the US.
  • Shorla aims to continuously bring products to market with a significant and growing portfolio of late-stage assets.

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

Retrieved on: 
Dienstag, Oktober 3, 2023
OT, United States Department of Health and Human Services, ASPR, Office of Inspector General, U.S. Department of Health and Human Services, Nextgen, Biomedical Advanced Research and Development Authority, Therapy, CBRN, HHS, Human services, OTA, COVID-19, Infection, Administration for Strategic Preparedness and Response, Hope, MBA, Research, Government, Wind, Administration, Development, Division, SAN, BARDA, Radiation, Vaccine, Hook effect

SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR), has awarded Vir approximately $50 million in new funding to advance the development of novel monoclonal antibody (mAb) candidates and delivery solutions to widen the applicability of mAbs in COVID-19 and in pandemic preparedness and response.

Key Points: 
  • “We are grateful to the U.S. government for its continued support of our innovative technological approaches in mAb research and development as we seek to optimize mAb delivery.
  • Such delivery could widen the breadth of administration options and shorten development and manufacturing timelines.
  • The new investment falls under Vir’s existing Other Transaction Authority (OTA), a multi-year contract BARDA awarded Vir in 2022 .
  • This OTA allows for a potential total investment of up to $1 billion to support Vir’s development of future pandemic influenza mAbs as well as the potential development of up to 10 emerging infectious disease or CBRN medical countermeasure candidates.

FTC Staff Submit Comment Supporting Proposed Amendments to Regulations Implementing the Mental Health Parity and Addiction Equity Act

Retrieved on: 
Montag, Oktober 2, 2023
Consumer protection, Insurance, U.S. Department of the Treasury, Office of Inspector General, Suds, Office of Inspector General, U.S. Department of Health and Human Services, Marketing, Human services, Commission, United States Department of Health and Human Services, Tic disorder, Blog, Federal Trade Commission, Bell Trade Act, Treasury, United States Department of Labor, FTC, Comment, SUD, Consumer, News, Social media, Dietary supplement

Staff in the Federal Trade Commission’s Bureau of Consumer Protection have submitted a comment to the U.S. Department of the Treasury, U.S. Department of Labor, and U.S. Department of Health and Human Services supporting proposed amendments to regulations implementing the Mental Health Parity and Addiction Equity Act.

Key Points: 
  • Staff in the Federal Trade Commission’s Bureau of Consumer Protection have submitted a comment to the U.S. Department of the Treasury, U.S. Department of Labor, and U.S. Department of Health and Human Services supporting proposed amendments to regulations implementing the Mental Health Parity and Addiction Equity Act.
  • The comment further details how the FTC has used additional enforcement tools included in the 2018 Opioid Addiction Recovery Fraud Prevention Act (OARFPA) to combat SUD treatment scams.
  • The comment noted that the proposed amendments strike the right balance between leaving intact previous enforcement systems while promoting better insurance coverage for SUD treatment.
  • Follow the FTC on social media, read consumer alerts and the business blog, and sign up to get the latest FTC news and alerts.